Substituted pyrazoles as IRAK inhibitors

1. A compound of Formula (II):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,

wherein:

R″ is H, C 1-6 aliphatic, C 3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted;

R 1 is absent or R 1 is A or Q-R;

R a is absent or R a is OR 3 , CF 3 , Hal, or NO 2 ;

R b is absent or R b is A or COR;

R 2 is

Q is a linear or branched alkylene, having 1 to 6 carbon atoms wherein 1-5 H atoms may be replaced by a group independently selected from OR 3 , Hal, or N(R 3 ) 2 , and wherein 1 or 2 CH 2 groups may be replaced by a group independently selected from CO, SO, SO 2 and NR 3 , or Q denotes a 4-8-membered bivalent heterocyclic ring, which is saturated, unsaturated or aromatic and which contains 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

each A is independently a linear or branched alkyl having 1 to 10 carbon atoms wherein 1 to 7 H atoms may be replaced by a group independently selected from —OR 3 , Hal, NHSO 2 A, SO 2 A, SOA, or N(R 3 ) 2 , and wherein 1, 2 or 3 non-adjacent —CH 2 — groups may be replaced by a group independently selected from —CO—, NR 3 and/or —O—;

each Hal is independently F, Cl, Br or I;

each R is independently hydrogen, C 1-6 aliphatic, C 3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted;

each R 3 is H or C 1-6 alkyl wherein 1 H atom may be replaced by a group selected from OH, —O—C 1-6 alkyl, and Hal; and

n is 0 or 1;

wherein optionally substituted for R″ and R means substituted at each substitutable position of the group, and when more than one position is substituted the substituent is the same or different, and the substituent is selected from the group consisting of: deuterium;

halogen; —(CH 2 ) 0-4 R ∘ ; —(CH 2 ) 0-4 OR ∘ ; —O(CH 2 ) 0-4 R ∘ , —O—(CH 2 ) 0-4 C(O)OR ∘ ; —(CH 2 ) 0-4 CH(OR ∘ ) 2 ; —(CH 2 ) 0-4 SR ∘ ; —(CH 2 ) 0-4 Ph which is optionally substituted with R ∘ ; —(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph which is optionally substituted with R ∘ ; —CH═CHPh which is optionally substituted with R ∘ ; —(CH 2 ) 0-4 O(CH 2 ) 0-1 -pyridyl which is optionally substituted with R ∘ ; —NO 2 ; —CN; —N 3 ; —(CH 2 ) 0-4 N(R ∘ ) 2 ; —(CH 2 ) 0-4 N(R ∘ )C(O)R ∘ ; —N(R ∘ )C(S)R ∘ ; —(CH 2 ) 0-4 N(R ∘ )C(O)NR ∘ 2 ; —N(R ∘ )C(S)NR ∘ 2 ; —(CH 2 ) 0-4 N(R ∘ )C(O)OR ∘ ; —N(R ∘ )N(R ∘ )C(O)R ∘ ; —N(R ∘ )N(R ∘ )C(O)NR ∘ 2 ; —N(R ∘ )N(R ∘ )C(O)OR ∘ ; —(CH 2 ) 0-4 C(O)R ∘ ; —C(S)R ∘ ; —(CH 2 ) 0-4 C(O)OR ∘ ; —(CH 2 ) 0-4 C(O)SR ∘ ; —(CH 2 ) 0-4 C(O)OSiR ∘ 3 ; —(CH 2 ) 0-4 OC(O)R ∘ ; —OC(O)(CH 2 ) 0-4 SR ∘ , SC(S)SR ∘ ; —(CH 2 ) 0-4 SC(O)R ∘ ; —(CH 2 ) 0-4 C(O)NR ∘ 2 ; —C(S)NR ∘ 2 ; —C(S)SR ∘ ; —SC(S)SR ∘ , —(CH 2 ) 0-4 OC(O)NR ∘ 2 ; —C(O)N(OR ∘ )R ∘ ; —C(O)C(O)R ∘ ; —C(O)CH 2 C(O)R ∘ ; —C(NOR ∘ )R ∘ ; —(CH 2 ) 0-4 SSR ∘ ; —(CH 2 ) 0-4 S(O) 2 R ∘ ; —(CH 2 ) 0-4 S(O) 2 OR ∘ ; —(CH 2 ) 0-4 OS(O) 2 R ∘ ; —S(O) 2 NR ∘ 2 ; —(CH 2 ) 0-4 S(O)R ∘ ; —N(R ∘ )S(O) 2 NR ∘ 2 ; —N(R ∘ )S(O) 2 R ∘ ; —N(OR ∘ )R ∘ ; —C(NH)NR ∘ 2 ; —P(O) 2 R ∘ ; —P(O)R ∘ 2 ; —OP(O)R ∘ 2 ; —OP(O)(OR ∘ ) 2 ; —SiR ∘ 3 ; —(C 1-4 straight or branched)alkylene)O—N(R ∘ ) 2 ; and —(C 1-4 straight or branched alkylene)C(O)O—N(R ∘ ) 2 ; wherein each R ∘ is optionally substituted as defined below and is independently selected from the group consisting of hydrogen, C 1-6 aliphatic alkyl, —CH 2 Ph, —O(CH 2 ) 0-1 Ph, —CH 2 -(5-6 membered heteroaryl ring), and a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, optionally, two independent occurrences of R ∘ , taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

the optional substituents for R ∘ or a ring formed by two independent occurrences of R ∘ together with their intervening atoms are independently selected from the group consisting of: deuterium, halogen, —(CH 2 ) 0-2 R ● , -(haloR ● ), —(CH 2 ) 0-2 OH, —(CH 2 ) 0-2 OR ● , —(CH 2 ) 0-2 CH(OR ● ) 2 ; —O(haloR ● ), —CN, —N 3 , —(CH 2 ) 0-2 C(O)R ● , —(CH 2 ) 0-2 C(O)OH, —(CH 2 ) 0-2 C(O)OR ● , —(CH 2 ) 0-2 SR ● , —(CH 2 ) 0-2 SH, —(CH 2 ) 0-2 NH 2 , —(CH 2 ) 0-2 NHR ● , —(CH 2 ) 0-2 NR ● 2 , —NO 2 , —SiR ● 3 , —OSiR ● 3 , —C(O)SR ● , —(C 1-4 straight or branched alkylene)C(O)OR ● , or —SSR ● , wherein each R ● is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from the group consisting of: C 1-4 aliphatic alkyl, —CH 2 Ph, —O(CH 2 ) 0-1 Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

or an optional substituent for R ∘ , when on a saturated carbon atom of R ∘ , is a divalent substituent ═O or ═S.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 is absent.

3. The compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R a is absent.

4. The compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R b is absent.

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

6. A pharmaceutical formulation comprising a pharmaceutically acceptable excipient or adjuvant and at least one compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

7. The pharmaceutical formulation of claim 6 , wherein the pharmaceutical formulation comprises at least one further medicament.

8. A kit consisting of separate packs of:

(a) an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof; and

(b) an effective amount of a further active medicament.

9. A method for inhibiting interleukin-1 receptor-associated kinase activity in a subject having a disease selected from the group consisting of an inflammatory disease, an autoimmune disorder, multiple sclerosis and cancer, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

10. The method of claim 9 , wherein the subject has an inflammatory disease or an autoimmune disorder selected from the group consisting of rheumatoid arthritis, lupus nephritis and systemic lupus erythematosus.

11. The method of claim 9 , wherein the autoimmune disorder is selected from the group consisting of acute disseminated encephalomyelitis, Addison's disease, alopecia areata, ankylosing spondylitis, antiphospholipid antibody syndrome, asthma, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, Behcet's disease, Coeliac disease, anti-transglutaminase, Chagas disease, chronic obstructive pulmonary disease, Crohn's disease, dermatomyositis, diabetes mellitus type 1, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, hidradenitis suppurativa, Kawasaki disease, immunoglobin A nephropathy, idiopathic thrombocytopenic purpura, interstitial cystitis, lupus erythematosus, mixed connective tissue disease, morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, schizophrenia, scleroderma, Sjogren's syndrome, stiff person syndrome, systemic sclerosis, temporal arteritis, ulcerative colitis, vasculitis, vitiligo and Wegener's granulomatosis.